Julia Ellert

TCT-90 Clinical Outcomes Three Year After Revascularization With a Biodegradable Polymer Ultra-thin Strut Sirolimus-eluting Stent and a Biodegradable Polymer Biolimus-eluting Stent. From the SORT OUT VII trial.

Polymer materials used for the first and second generation drug-eluting stents (DES) may trigger chronic inflammatory responses that can lead to late adverse outcomes. DES with biodegradable polymers could have the potential to abolish these late events. However, DES with biodegradable polymers may

Impact of diabetes on clinical outcomes after revascularization with sirolimus-eluting and biolimus-eluting stents with biodegradable polymer from the SORT OUT VII trial

In this substudy of the SORT OUT VII trial, the clinical outcomes among patient with diabetes mellitus treated with Orsiro sirolimus‐eluting stent (O‐SES; Biotronik, Bülach, Switzerland) or Nobori biolimus‐eluting stent (N‐BES; Terumo, Tokyo, Japan) were compared.

Early restenose in a polymer-free Biolimus A9-coated stent (BioFreedom): A case report based on optical coherence tomography

An 81-year-old male patient with a severe de novo coronary artery stenosis in the proximal left anterior descending artery was treated with a BioFreedom stent (3.5×11mm), three months later, the patient was re-admitted with chest pain and slightly increased troponin. The angiogram showed a significant in-stent restenosis in the recently treated lesion. Optical coherence tomography revealed a fully expanded stent without areas of incomplete stent apposition. Severe immature neointimal hyperplasia without formation of thrombosis was visualized, causing a severe in-stent restenosis. An underlying plaque rupture within the mid-proximal part of the in-stent restenosis was evident.

TCT-245 Association of intraoperative transit time flow after grafting and invasive coronary flow and pressure measurements before coronary artery bypass surgery.

RESULTS 1,555 patients were included; 861 underwent PCI and 694 underwent CABG (Table 1). Patients with index PCI were more often female, African American, presented with ST-elevation MI, and had previous MI; they were less often diabetic, had congestive heart failure, proximal left anterior descending disease, or presented with stable angina. The rate of 10-year MACCE was 67.3% among PCI patients and 54.1% among CABG patients (p < 0.0001) and of RR was 24.7% vs. 12.0%. Adjusting for baseline covariates, the odds ratio of RR for patients with index CABG was 0.45 (0.28 – 0.72, pvalue < 0.0001). 57 patients with index CABG were found to have 1 occluded graft on subsequent angiography without RR; of these, 48 had inadequate targets for intervention.

TCT-261 Impact of Diabetes on Clinical Outcomes after Revascularization with Sirolimus-eluting and Birolimus-Eluting Stents with biodegradable polymer. From the SORT OUT VII Trial

Diabetes is associated with increased risk of target lesion failure after percutaneous coronary intervention. In this substudy of the SORT OUT VII ([NCT01879358][1]) trial we compared the clinical outcome among patient with and without diabetes mellitus treated with sirolimus-eluting stent (O-SES,